FDA Prepares To Issue Draft Biomarker Qualifications Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
The document should provide an "important boost" to employing genetic, genomic and protein-based markers to improve the efficiency of preclinical and clinical drug studies and make them more likely to succeed, Commissioner Hamburg told the Personalized Medicine Coalition.